STOCK TITAN
  1. Home
  2. News
  3. GANX

Gain Therapeutics Inc - GANX STOCK NEWS

Welcome to our dedicated news page for Gain Therapeutics (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gain Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gain Therapeutics's position in the market.

News
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
Rhea-AI Summary
Gain Therapeutics, Inc. appoints Gene Mack as CFO, bringing 25 years of experience in life sciences. Mack to lead financial strategies and advance lead drug candidate GT-02287 for Parkinson's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
management
-
News
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
Rhea-AI Summary
Gain Therapeutics, Inc. appoints Dr. Jonas Hannestad as Chief Medical Officer, bringing extensive experience in CNS drug development. Dr. Hannestad will lead the advancement of GT-02287 program for Parkinson's disease. The Company also grants him an option to purchase 200,000 shares of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
management
-
News
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
Rhea-AI Summary
Gain Therapeutics, Inc. (Nasdaq: GANX) reports financial results for 2023, highlighting progress in developing small molecule therapies for Parkinson's disease. The company presented data on lead compound GT-02287, initiated Phase 1 clinical trials, and raised $10.1 million. However, increased R&D and G&A expenses led to a net loss of $22.3 million for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
earnings
News
Gain Therapeutics to Present at Public Ventures Discovery Day
Rhea-AI Summary
Gain Therapeutics' Former CEO and current Board Member to participate in fireside chat hosted by Public Ventures President and Aberdeen Investment Management President.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
conferences
-
News
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
Rhea-AI Summary
Gain Therapeutics, Inc. (GANX) presents data at AD/PD™ 2024 on GT-02287's ability to prevent GCase misfolding and dysfunction in Parkinson's disease. The compound aids correct GCase folding, enhancing lysosomal activity and processing of glucosylceramide. The study, in collaboration with Professor Molinari's group, highlights the mechanism of action of GT-02287 in preventing cellular stress and dysfunction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
-
News
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Rhea-AI Summary
Gain Therapeutics, Inc. (GANX) announces the initiation of the Multiple Ascending Dose (MAD) part of the Phase 1 clinical trial of GT-02287 for GBA1 Parkinson’s disease. The trial remains on track with positive safety and tolerability profiles observed in earlier cohorts. GT-02287 has shown promising preclinical data in restoring motor function and reducing neurodegeneration biomarkers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
clinical trial
News
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
Rhea-AI Summary
Gain Therapeutics, Inc. (GANX) to hold a 2024 Research & Development update on February 22, 2024, focusing on GT-02287 in vivo data for Parkinson's Disease. Key Opinion Leaders to provide insights on unmet medical needs and therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
none
-
News
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Rhea-AI Summary
Gain Therapeutics, Inc. (Nasdaq: GANX) presents preclinical data at the 20th WORLDSymposium™, demonstrating the neuroprotective effects and motor function restoration of its clinical-stage GCase regulator GT-02287 in Parkinson's disease models. The data show a progressive reversal of motor deficit and a reduction of the neurodegeneration biomarker NfL to the level of the control arm. The company is currently conducting a Phase 1 clinical trial of GT-02287 in healthy adults and plans to commence treatment of patients in an extension of that clinical trial in Q3 of this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
none
-
News
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
Rhea-AI Summary
Gain Therapeutics, Inc. releases a letter to stockholders from its CEO, Matthias Alder, highlighting the progress of the company in 2023 and its strategy for 2024. They focus on the development of their lead drug candidate for Parkinson's disease, GT-02287, and present preclinical data supporting its potential. Additionally, they discuss the upgrade of their computational drug discovery platform, Magellan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
Rhea-AI Summary
Gain Therapeutics, Inc. (Nasdaq: GANX) announced new data of GT-02287 in preclinical models of Parkinson’s disease accepted for a platform presentation at the 20th Annual WORLDSymposium™. The presentation will focus on GT-02287, a clinical stage GCase enhancer, displaying neuroprotection and restoring motor function in preclinical models of Parkinson’s disease following delayed administration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.03%
Tags
none
Stock GANX logo
Gain Therapeutics Inc

Nasdaq:GANX

GANX Rankings

#4687 Ranked by Market Cap
#2931 Ranked by Stock Gains
N/A Ranked by Dividends

GANX Stock Data

51.09M
14.26M
16.45%
10.33%
0.85%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Bethesda

About GANX

gain therapeutics is a preclinical stage biotech company specializing in the discovery of new drugs for orphan diseases. the company targets inborn errors of metabolism; a group of rare diseases of genetic origin with a high unmet medical need. gain therapeutics is also working on a new class of compounds: non-competitive pharmacological chaperones, identified through its innovative proprietary platform – see-tx. the gain therapeutics team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma.